Immunology, Nephrology
Conditions
Keywords
ESRD, hemodialysis, hemodiafiltration, influenza vaccine, immune response
Brief summary
On-line hemodiafiltration (HDF) clears more azotaemic toxins compared to high-flux hemodialysis (HD). The response to vaccination is impaired in dialysis patients. We aimed to study the immune responses to influenza vaccine in dialysis patients treated by HDF vs. HD.
Interventions
BIOLOGICALInfluenza vaccine
A single standard dose of inactivated trivalent influenza vaccine: Influvac® vaccines (Abbott, the Netherlands), intramuscularly.
Sponsors
Bhumirajanagarindra Kidney Institute, Thailand
Ministry of Health, Thailand
Mahidol University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Masking description
Open label
Intervention model description
* A prospective cohort study in chronic dialysis patients during the 2016 and 2017 influenza seasons * All participants received a single standard dose of trivalent influenza vaccine * The elicited humoral immune response by hemagglutination inhibition test, and cell-mediated immune response by enumeration of lymphocyte cellular markers and proliferation assays are studied.
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
\- ESRD patients aged 18 years or older, who had been treated for more than one month of either thrice weekly on-line hemodiafiltration (HDF) or conventional high flux hemodialysis (HD), with a session dialyzer urea clearance (Kt/V urea) of 1.2 and greater, with a convection volume target of 20 L/session for the HDF group
Exclusion criteria
* Had received any vaccination within the previous four weeks, or influenza vaccination within six months * Patient who reported upper respiratory tract symptoms within three days prior to the study vaccination * A history of allergy to influenza vaccine or egg * Thrombocytopenia * In receipt of immunosuppressant medications, chemotherapy, or had immunodeficiency
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| measurement antibody titers, determined by hemagglutination inhibition (HI) assay. | 12 months | measurement antibody titers, determined by hemagglutination inhibition (HI) assay. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| measurement T cell subpopulations, determined by flow cytometer AND cell proliferation assay after stimulated with influenza viruses. | 12 months | measurement T cell subpopulations, determined by flow cytometer AND cell proliferation assay after stimulated with influenza viruses. |
Outcome results
None listed